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CD8+ T-cell deﬁciency is a feature of many chronic autoimmune diseases, including multiple sclerosis, rheumatoid arthritis,
systemic lupus erythematosus, Sj¨ ogren’s syndrome, systemic sclerosis, dermatomyositis, primary biliary cirrhosis, primary
sclerosing cholangitis, ulcerative colitis, Crohn’s disease, psoriasis, vitiligo, bullous pemphigoid, alopecia areata, idiopathic
dilated cardiomyopathy, type 1 diabetes mellitus, Graves’ disease, Hashimoto’s thyroiditis, myasthenia gravis, IgA nephropathy,
membranous nephropathy, and pernicious anaemia. It also occurs in healthy blood relatives of patients with autoimmune
diseases, suggesting it is genetically determined. Here it is proposed that this CD8+ T-cell deﬁciency underlies the development
of chronic autoimmune diseases by impairing CD8+ T-cell control of Epstein-Barr virus (EBV) infection, with the result that
EBV-infected autoreactive B cells accumulate in the target organ where they produce pathogenic autoantibodies and provide
costimulatory survival signals to autoreactive T cells which would otherwise die in the target organ by activation-induced
apoptosis. Autoimmunity is postulated to evolve in the following steps: (1) CD8+ T-cell deﬁciency, (2) primary EBV infection,
(3) decreased CD8+ T-cell control of EBV, (4) increased EBV load and increased anti-EBV antibodies, (5) EBV infection in the
target organ, (6) clonal expansion of EBV-infected autoreactive B cells in the target organ, (7) inﬁltration of autoreactive T cells
into the target organ, and (8) development of ectopic lymphoid follicles in the target organ. It is also proposed that deprivation
of sunlight and vitamin D at higher latitudes facilitates the development of autoimmune diseases by aggravating the CD8+ T-cell
deﬁciency and thereby further impairing control of EBV. The hypothesis makes predictions which can be tested, including the
prevention and successful treatment of chronic autoimmune diseases by controlling EBV infection.
1.Introduction
Epstein-Barr virus (EBV) has been suspected of involvement
in the pathogenesis of various chronic autoimmune diseases
since the ﬁnding of elevated levels of antibody to the
virus in systemic lupus erythematosus (SLE) in 1971 [1].
Generally the eﬀect of EBV infection has been attributed
to immunological cross-reactivity between EBV and self-
antigens [2–4]; however, in 2003 the EBV-infected autore-
active B-cell hypothesis of autoimmunity was proposed
as the basis for human chronic autoimmune diseases [5].
This hypothesis proposes that, in genetically susceptible
individuals, EBV-infected autoreactive B cells seed the target
organ where they produce pathogenic autoantibodies and
provide costimulatory survival signals to autoreactive T
cells which would otherwise die in the target organ by
activation-induced apoptosis [5]( Figure 1). The present
article presents a further development of this hypothesis,
proposingthatsusceptibilitytodevelopchronicautoimmune
diseases after EBV infection is dependent on a genetically
determined quantitative deﬁciency of the cytotoxic CD8+
T cells that normally keep EBV infection under tight con-
trol. It is postulated that autoimmunity evolves in the fol-
lowing steps: (1) CD8+ T-cell deﬁciency; (2) primary EBV
infection; (3) decreased CD8+ T-cell control of EBV; (4)
increased EBV load and increased anti-EBV antibodies; (5)
EBV infection in the target organ; (6) clonal expansion of
EBV-infected autoreactive B cells in the target organ; (7)
inﬁltration of autoreactive T cells into the target organ; and
(8) development of ectopic lymphoid follicles in the target
organ (Figure 2).2 Autoimmune Diseases
The evidence for each of these steps is considered in
turn after a general introduction to EBV. There follows a
summary of the proposed scenario for the development of
autoimmune diseases and suggested strategies for testing the
hypothesis.
2.EBV
EBV is a ubiquitous human herpesvirus that has the unique
ability to infect, activate, and latently persist in B lym-
phocytes for the lifetime of the infected individual. During
primary infection, EBV transmitted via saliva infects na¨ ıve
B cells in the tonsil through the binding of the viral surface
glycoprotein gp350 to complement receptor 2 (also known
as CD21), which is expressed by mature B-cells and follicular
dendritic cells [6] .E B Vd r i v e st h ei n f e c t e dBc e l lo u to f
the resting state to become an activated B blast and then
exploits the normal pathways of B cell diﬀerentiation so that
the B blast diﬀerentiates in a germinal centre to become
a latently infected resting memory B cell which exits from
the germinal centre and circulates in the blood [7]. Latently
infectedmemoryBcellsreturningtothetonsilcanterminally
diﬀerentiate into plasma cells, which initiates the lytic
(replicative)cyclewiththeproductionofinfectiousvirus[8].
The resulting free virions infect tonsil epithelial cells where
the virus replicates at a high rate and is continuously shed
into saliva for transmission to new hosts [9]. Newly formed
virus can also infect additional na¨ ıve B cells in the same
host.
Latently infected memory B cells display the molecular
hallmarks of classical antigen-selected memory B cells,
namely, somatic hypermutation and class-switch recombi-
nation of their immunoglobulin (Ig) genes [10]. In normal
B-cell diﬀerentiation, na¨ ıve B cells are activated by antigen
through the B-cell receptor (BCR) and by T-cell help
through the CD40 receptor so that they proliferate and
progress through a germinal centre reaction. Remarkably,
EBV expresses two proteins, latent membrane protein 2A
(LMP2A) and LMP1, which mimic the antigen-activated
BCR and the activated CD40 receptor, respectively [11,
12]. In the tonsil LMP2A and LMP1 appear to work
synergistically with BCR signalling and CD40 signalling,
respectively [13].
EBV infection is normally kept under tight control by
EBV-speciﬁc immune responses, especially by cytotoxic
CD8+ T cells which eliminate proliferating and lytically
infected B cells [14]. In the developing world most children
become infected within the ﬁrst three years of life, and
EBV seropositivity reaches 100% within the ﬁrst decade
[15]. These early primary infections are almost always
asymptomatic. In contrast, in the developed world, up to
half the children are still EBV seronegative at the end
of their ﬁrst decade and subsequently become infected
through intimate oral contact in adolescence or young
adulthood [15]. As many as 50% of these delayed primary
infections are symptomatic and manifest as acute infectious
mononucleosis.
3. Steps to Autoimmunity
3.1. Step 1: CD8+ T-Cell Deﬁciency. Since 1980 it has been
recognized that the proportion and number of CD8+ T cells
in the peripheral blood are decreased and that the CD4/CD8
ratio is increased in patients with autoimmune diseases,
including multiple sclerosis (MS) [16–21], rheumatoid
arthritis (RA) [22, 23], SLE [24, 25], Sj¨ ogren’s syndrome [25,
26], systemic sclerosis [27, 28], dermatomyositis [29, 30],
primary biliary cirrhosis [31], primary sclerosing cholangitis
[32],ulcerativecolitis[33,34],Crohn’sdisease[33],psoriasis
[35], vitiligo [36, 37], bullous pemphigoid [38, 39], alopecia
areata [40], idiopathic dilated cardiomyopathy [41, 42],
type 1 diabetes mellitus [43–46], Graves’ disease [47, 48],
Hashimoto’s thyroiditis [47, 49], myasthenia gravis [50, 51],
IgA nephropathy [52, 53], membranous nephropathy (or
membranous glomerulonephritis) [52, 53], and pernicious
anaemia [54, 55]. Although some studies have not found
CD8+T-celldeﬁciencyinpatientswithautoimmunediseases
[56] or have attributed the deﬁciency to hormonal factors
[57], CD8+ T-cell deﬁciency would appear to be a general
feature of human chronic autoimmune diseases. This was
initially interpreted as a decrease in suppressor CD8+ T cells
leading to disinhibition of autoimmune responses [16, 22,
24, 47, 50] but later attributed to sequestration of CD8+
T cells in the target organ [19, 23, 31] because CD8+ T
cells are selectively enriched compared to CD4+ T cells in
the target organ in some autoimmune diseases [23, 58].
However, if CD8+ T cells are accumulating in the target
organ because of the presence of EBV, the number of
CD8+ T cells in the blood should increase, not decrease,
because normally the CD8+ T-cell response increases with
EBV load [59–61]. An alternative explanation, and the one
proposed here, is that a genetic deﬁciency of CD8+ T cells
results in a decreased CD8+ T-cell response to EBV, which
allows EBV-infected B cells to accumulate in the target
organ.
The CD4/CD8 T-cell ratio in humans is genetically
controlled [62], with at least some of the responsible genes
being located in the HLA complex [63]. The CD8+ T cell
deﬁciency and increased CD4/CD8 ratio in autoimmune
diseases are also present in the healthy blood relatives of
patients with these diseases [36, 45, 46, 64, 65], indicating
that the abnormalities are genetically determined and not
secondary to the disease process. Interestingly, females gen-
erally have lower proportions and numbers of CD8+ T cells,
higherproportionsandnumbersofCD4+Tcells,andhigher
CD4/CD8ratiosthanmales[62,66–70].Thesegenderdiﬀer-
ences appear to be hormonally mediated because oestrogen
deﬁciencysubstantiallyincreasestheproportionandnumber
of CD8+ T cells and decreases the CD4/CD8 ratio, with the
ratiodirectlycorrelatingwiththeserumoestradiollevel[71].
Lower numbers of CD8+ T cells in females might contribute
to the higher frequency of autoimmune diseases in females
than males. Because the number of CD8+ T cells normally
declines with increasing age, particularly through childhood
[72], but also through adulthood [62, 70, 73], the primary
CD8+ T cell deﬁciency will be aggravated as each person
ages, as occurs in patients with MS [74]( Figure 3).Autoimmune Diseases 3
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Figure 1: Proposed role of EBV infection in the development of chronic autoimmune diseases. During primary infection EBV infects
autoreactive na¨ ıve B cells in the tonsil, driving them to enter germinal centres where they proliferate and diﬀerentiate into latently infected
autoreactive memory B cells (path 1) which then exit from the tonsil and circulate in the blood (path 2). The number of EBV-infected B
cells is normally controlled by EBV-speciﬁc cytotoxic CD8+ T cells, which kill proliferating and lytically infected B cells, but not if there is a
defect in this defence mechanism. Surviving EBV-infected autoreactive memory B cells enter the target organ where they take up residence
and produce oligoclonal IgG and pathogenic autoantibodies which attack components of the target organ (path 3). Autoreactive T cells that
have been activated in peripheral lymphoid organs by cross-reacting foreign antigens circulate in the blood and enter the target organ where
they are reactivated by EBV-infected autoreactive B cells presenting target organ peptides (Tp) bound to major histocompatibility complex
(MHC) molecules (path 4). These EBV-infected B cells provide costimulatory survival signals (B7) to the CD28 receptor on the autoreactive
T cells and thereby inhibit the activation-induced T-cell apoptosis which normally occurs when autoreactive T cells enter the target organ
and interact with nonprofessional antigen-presenting cells (APCs) which do not express B7 costimulatory molecules [168, 169]( P a t h6 ) .
After the autoreactive T cells have been reactivated by EBV-infected autoreactive B cells, they produce cytokines such as interleukin-2 (IL2),
interferon-γ (IFNγ) and tumour necrosis factor-β (TNFβ) and orchestrate an autoimmune attack on the target organ (Path 5). BCR, B cell
receptor; TCR, T cell receptor.
Exposure to natural sunlight or treatment in a solarium
increases the proportion of CD8+ T cells and decreases the
CD4/CD8 T cell ratio in peripheral blood [75–77]. Exactly
how sunlight increases the number of CD8+ T cells is
unclear, but the eﬀect is probably mediated at least in part
by vitamin D because (1) among cells of the immune system,
activated CD8+ T cells express the highest concentrations
of the vitamin D receptor [78]; (2) vitamin D increases the
mitogen-inducedproliferationofCD8+Tcellsanddecreases
the CD4/CD8 ratio in bovine peripheral blood mononuclear
cells in vitro [79]; (3) vitamin D administration increases
the CD8+ T cell count [80]; (4) vitamin D deﬁciency is
associated with a decreased proportion of CD8+ T cells
and increased CD4/CD8 ratio [81]. Here it is proposed4 Autoimmune Diseases
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Severe autoimmunity
Mild
autoimmunity
Health
+ ↓Sunlight
Severe genetic ↓
Age
Mild genetic ↓
CD8+ T cells
CD8+ T cells
C
D
8
+
T
 
c
e
l
l
s
Figure 3: Proposed genetic deﬁciency of CD8+ T cells underlying the development of chronic autoimmune diseases. The upper green panel
on the graph represents health, the middle orange panel, the development of mild autoimmune disease (mild autoimmunity) and the lower
red panel the development of severe progressive autoimmune disease (Severe autoimmunity). In normal individuals (Health) the number of
CD8+ T cells declines with increasing age but still remains suﬃcient to control EBV infection. In individuals with a mild genetic deﬁciency
of CD8+ T cells, the deﬁciency is aggravated by increasing age eventually leading to insuﬃcient CD8+ T cells to control EBV infection.
In individuals carrying HLA class II or class I genes predisposing to speciﬁc autoimmune diseases, this leads to the accumulation of EBV-
infected B cells in the target organ and the development of autoimmune disease, which progresses in severity as the CD8+ T-cell count
further declines with age and as the EBV load in the target organ subsequently increases. In individuals with a severe genetic deﬁciency of
CD8+ T cells, autoimmune diseases develop at a younger age and progress more rapidly. Deprivation of sunlight and vitamin D at higher
latitudes aggravates the genetic CD8+ T-cell deﬁciency and increases the incidence and progression of autoimmune disease.
that deprivation of sunlight and vitamin D aggravates the
genetically determined CD8+ T cell deﬁciency and impaired
control of EBV infection and thereby contributes to the
high prevalence of autoimmune diseases such as MS, type
1 diabetes, and RA at high latitudes [82–84]( Figure 3)a n d
that the protective eﬀect of vitamin D against autoimmune
diseases [85–87] is mediated at least in part by an increase
in the number of CD8+ T cells available to control EBV.
A higher frequency of late primary EBV infection at higher
latitude might also contribute to the latitudinal gradient
[88].
3.2. Step 2: Primary EBV Infection. Patients with MS are
almost universally (>99%) seropositive for EBV, but not for
other viruses [89, 90]. In a meta-analysis of 13 case-control
studiescomparingEBVserologyinMSpatientsandcontrols,
99.5% of MS patients were EBV seropositive compared to
94.0% of controls, with EBV seronegativity having an ORMH
odds ratio of MS of 0.06 (exact 95% CI: 0.03, 0.13; P<
0.000000001) [91]. Serial studies have shown that the risk
of developing MS is extremely low among individuals not
infectedwithEBVbutincreasessharplyinthesameindividu-
als following EBV infection, with an estimated mean intervalAutoimmune Diseases 5
of 5.6 years between primary EBV infection and onset of MS
[92]. These studies suggest that EBV infection is essential
for the development of MS but, by itself, is not suﬃcient
to cause MS because the vast majority of people infected
with EBV do not develop the disease [93]. The dramatic
increase in MS risk following primary EBV infection [92]i s
obscured by the fact that EBV infects such a large proportion
(∼95%) of the general adult population. If EBV does have an
essential role in the development of MS, studies in children
should show a larger numerical diﬀerence in the frequency
of EBV seropositivity between MS patients and controls
because the prevalence of EBV infection in the general
population is considerably lower in children than in adults.
Indeed, children with MS have an EBV-seropositivity rate
of 86–99% compared to 64–72% in age-matched controls
[94–96].
As with MS, virtually all patients with SLE are seroposi-
tive for EBV [97, 98]. This is particularly striking in children
and young adults where 99% of patients with SLE are EBV
seropositive compared to 70% of age-matched controls (P<
0.00000000001) [97]. The above ﬁndings strongly suggest
that EBV infection is a prerequisite for the development of
MSandSLE,raisingthepossibilitythatthesamemightapply
to other chronic autoimmune diseases [5]. Recent studies
have found all children with autoimmune hypothyroidism
to be EBV seropositive compared to 51.6% of age-matched
controls [99] and 98.5% of adults with Graves’ disease to
have antibodies to EBV nuclear antigens compared to 78.1%
of controls [100]. All patients with coeliac disease were
also found to be EBV seropositive in one study although
the seropositivity rate in controls was not documented
[101]. Studies of EBV seroprevalence are lacking in other
autoimmune diseases.
The age at which primary infection with EBV occurs
is also important. As discussed above in Section 2, when
primary EBV infection occurs in early childhood, as it
generally does in the developing world, it is asymptomatic
but when it is delayed to the time of adolescence or later,
as in the developed world, it commonly manifests as infec-
tious mononucleosis where the number of latently infected
memory B cells can rise to half, and perhaps even higher,
of the peripheral memory B cell compartment [102]. Why a
higherproportionofBcellsshouldbeinfectedwhenprimary
infection is delayed beyond childhood to adolescence or later
isunclear.Possibleexplanationsincludeahigherdoseofviral
inoculum acquired by intimate oral contact and a reduced
capacity to mount a rapid eﬀective CD8+ T-cell response in
adolescents/adultscomparedtoyoungchildren.Theabsolute
size of the CD8+ T-cell population in healthy individuals
decreases threefold between the ages of 2 and 16 years [72].
Here it is proposed that a genetically determined CD8+ T-
cell deﬁciency does not lead to impaired control of EBV
when primary infection occurs in early childhood, unless the
deﬁciency is severe, but that when primary infection occurs
in adolescence or adulthood after the normal age-related
precipitous decline in CD8+ T cells the same genetic CD8+
T-cell deﬁciency is more likely to impair control of EBV
infection. This might explain why infectious mononucleosis
increases the risk of MS [103] and why the prevalence of MS
is high when primary infection with EBV is delayed beyond
puberty [104]. The occurrence of EBV infection at a younger
age in children from less prosperous socioeconomic groups
[105] is likely to be an important contributor to the protec-
tion that substandard hygiene confers against autoimmunity
[106].
3.3. Step 3: Decreased CD8+ T-Cell Control of EBV. EBV
infection is normally kept under tight control by EBV-
speciﬁc immune responses, especially by cytotoxic CD8+ T
cells, which eliminate proliferating and lytically infected B
cells [14]. CD8+ T cell control of EBV-infected B cells is
impaired in patients with autoimmune diseases, including
RA [107–109], SLE [110], Sj¨ o g r e n ’ ss y n d r o m e[ 111, 112],
MS [113, 114], primary biliary cirrhosis [115], and systemic
sclerosis [116]. In MS this defective control of EBV is not
due to increased B cell resistance to killing by cytotoxic
CD8+ T cells or to a functional impairment in the cytotoxic
ability of CD8+ T cells but results from a decrease in the
number of EBV-speciﬁc CD8+ T cells [114]. This in turn
stems from the general deﬁciency of CD8+ T cells and
from a decreased proportion of EBV-speciﬁc T cells within
the total CD8+ T-cell population [74]. The low proportion
of EBV-speciﬁc T cells within the CD8+ T-cell population
in MS has been proposed to be due to T-cell exhaustion
[74], which occurs in virus-speciﬁc CD8+ T cells during
high-grade chronic viral infections [117]. Deprivation of
sunlight and vitamin D will also aggravate the CD8+ T-cell
deﬁciencyandimpairedcontrolofEBV,asdiscussedabovein
Section 3.1.
3.4. Step 4: Increased EBV Load and Increased Anti-EBV
Antibodies. The EBV DNA load, as measured by the total
numberofviralgenomes,isincreasedinthebloodofpatients
with autoimmune diseases, including Sj¨ ogren’s syndrome
[118, 119], RA [120], SLE [121], primary biliary cirrhosis
[122], and inﬂammatory bowel disease [123]. Patients with
RA [109]a n dS L E[ 124] also have been shown to have an
increased frequency of EBV-infected B cells in their blood,
but whether this is the case in other autoimmune diseases
has not been determined.
The level of anti-EBV antibodies in the blood is also
increased in autoimmune diseases, including SLE [1], RA
[125], MS [126], idiopathic pulmonary ﬁbrosis (or crypto-
genic ﬁbrosing alveolitis) [127], Sj¨ ogren’s syndrome [128],
IgA nephropathy [129] and autoimmune thyroid disease
[130]. Elevation of anti-EBV antibodies precedes the onset
and increases the risk of MS [131–133]. Here it is proposed
that the increase in anti-EBV antibodies reﬂects an increased
EBV load consequent to the decreased CD8+ T-cell response
to EBV. The production of anti-EBV antibodies may also
be enhanced by increased help from CD4+ T cells, which
show increased reactivity to EBV in SLE [121]a n dM S
[134].
3.5. Step 5: EBV Infection in the Target Organ. In healthy
EBV-seropositive subjects, the frequency of EBV-infected B
cells in the peripheral blood is ∼5p e r1 0 6 B cells [135].
Thus it may be anticipated that a similar low frequency6 Autoimmune Diseases
of EBV-infected B cells will be found at any site of tissue
inﬂammation involving B cells, regardless of cause. For EBV-
infected B cells in the target organ to be incriminated in
the pathogenesis of autoimmunity, they should be found
at a substantially higher frequency than would occur if
the proportion of EBV-infected B cells within the B-cell
component of the tissue inﬁltrate simply reﬂected that in
the blood. The gold standard for detection of EBV-infected
B cells in histological material is in situ hybridization for
EBV-encoded small RNA (EBER-ISH) [136], which allows
determination of the frequency of EBV-infected B cells in
B-cell inﬁltrates. However, if the tissue viral load is deﬁned
as the total EBV genome copy number determined by the
polymerase chain reaction (PCR), then it is not possible to
determine whether a large increase in viral load is due to
a large increase in the frequency of latently infected B cells,
which express only two to ﬁve copies of the viral genome per
cell, or a very small increase in the fraction of infected cells
replicating the virus, which contain thousands of genomes
per cell [124]. The probability of detecting EBV in the target
organ is also inﬂuenced by the size of the tissue sample, with
a lower probability of detection in biopsies than in studies of
the whole organ [137].
Studies using EBER-ISH have found an increased fre-
quency of EBV-infected B cells in the salivary glands in
Sj¨ ogren’s syndrome [138, 139], the colon in ulcerative colitis
and Crohn’s disease [137, 140] ,t h eb r a i ni nM S[ 141],
the thymus in myasthenia gravis [142], and the thyroid
gland in Graves’ disease [100]. Studies using PCR alone
have shown increased levels of EBV DNA in the liver in
primary biliary cirrhosis [122], kidney in IgA nephropathy
and membranous nephropathy [143], and lung in idiopathic
pulmonary ﬁbrosis [144].
Whereas the concept of a target organ is clear in organ-
speciﬁcautoimmunity,itislesssoinsystemicautoimmunity.
In SLE, for example, tissue damage can be mediated either by
autoantibodies produced in lymphoid organs remote from
the targeted tissue or by direct lymphocytic inﬁltration of
nonlymphoidorganssuchasthekidney[145].ThusforSteps
5, 6, and 8 in systemic autoimmunity the term “target organ”
is extended to encompass not only targeted nonlymphoid
tissues inﬁltrated with lymphocytes, such as the kidney, but
also targeting lymphoid organs such as the bone marrow,
lymph nodes, and spleen which may be sites of clonal
expansion of EBV-infected autoreactive B cells.
3.6. Step 6: Clonal Expansion of EBV-Infected Autoreactive
B Cells in the Target Organ. Monoclonal or oligoclonal B-
cell expansion occurs in the thyroid gland in Hashimoto’s
thyroiditis [146], salivary glands in Sj¨ ogren’s syndrome [147,
148], synovium in RA [149, 150], cerebrospinal ﬂuid in MS
[151], liver in primary biliary cirrhosis [152], muscle in
dermatomyositis and polymyositis [153], and blood in SLE
[154]. These clonally expanded B cells exhibit the molecular
hallmarks of an antigen-driven germinal centre reaction,
namely, somatic hypermutation and high replacement-to-
silent mutation ratios in the complementarity-determining
regions of the Ig variable (V) region genes [148, 150, 151].
Autoreactive B cells have been demonstrated in the thyroid
gland in autoimmune thyroid disease [155, 156], salivary
glands in Sj¨ ogren’s syndrome [157], and liver in primary
biliary cirrhosis [158].
B-cell clonal expansion within the target organ has been
proposed to be due to EBV infection of autoreactive B cells
[5]. The probability of EBV infecting autoreactive B cells is
not low because at least 20% of human na¨ ıve B cells are
autoreactive [159]. Indeed, EBV infection of na¨ ıve B cells
of normal individuals in vitro results in the production of
monoclonal autoantibodies [160]. In healthy individuals,
most of the autoantibodies produced by autoreactive B cells
in vivo are of the IgM class and are nonpathogenic or “natu-
ral” antibodies [161]. However, in individuals with CD8+ T
cell deﬁciency, uncontrolled infection of na¨ ıve autoreactive
B cells by EBV in vivo could drive these cells through a
germinal centre reaction, with somatic hypermutation and
class-switch recombination resulting in the production of
pathogenic IgG or IgA autoantibodies. Memory B cells la-
tently infected with EBV display the same molecular hall-
marks of an antigen-driven germinal centre reaction [10]a s
those exhibited by clonally expanded B cells isolated from
target organs. As yet it has not been determined whether
clonally expanded and autoreactive B cells in target organs
are infected with EBV.
3.7. Step 7: Inﬁltration of Autoreactive T Cells into the
Target Organ. Inﬁltration of autoreactive T cells into the
target organ has been demonstrated by the isolation of
thyroid-speciﬁc T cells from the thyroid gland in Graves’
disease [162, 163], pyruvate dehydrogenase complex-speciﬁc
T cells from the liver in primary biliary cirrhosis [164, 165],
Ro(SSA)-speciﬁc T cells from the salivary glands in Sj¨ ogren’s
syndrome [166], and T cells speciﬁc for transglutaminase-
modiﬁed gliadin from duodenal mucosa in coeliac disease
[167]. In the case of primary biliary cirrhosis it has been
shown that there is a marked enrichment of autoreactive
CD4+ T cells and CD8+ T cells in the liver compared to
the peripheral blood [164, 165]. Here it is proposed that,
after activation in peripheral lymphoid organs by cross-
reacting foreign antigens, autoreactive T cells enter the
target organ where they are reactivated by EBV-infected B
cells which present self-antigens and provide costimulatory
survival signals, thereby inhibiting the activation-induced
T-cell apoptosis which normally occurs when autoreac-
tive T cells enter the target organ [168, 169]( Figure 1).
It is postulated that the inﬁltrating autoreactive T cells
then orchestrate an immune attack on the target organ
through the recruitment of macrophages and additional B
cells.
3.8. Step 8: Development of Ectopic Lymphoid Follicles in
the Target Organ. A frequent ﬁnding in organs targeted by
autoimmunity is the presence of ectopic lymphoid tissue
containing B-cell follicles with germinal centres, which may
represent sites of clonal expansion of autoreactive B cells
speciﬁc for antigens present in the target organ. Such ectopic
B-cell follicles are found in the gut in Crohn’s disease [170]
and ulcerative colitis [171], the liver in primary biliary
cirrhosis [172], the thyroid gland in Hashimoto’s thyroiditisAutoimmune Diseases 7
[156, 173] and Graves’ disease [156], the synovium in RA
[174, 175] and psoriatic arthritis [176], the lung in idio-
pathic pulmonary ﬁbrosis [177, 178], the salivary glands
in Sj¨ ogren’s syndrome [157, 179], the brain in MS [180,
181], the kidney in membranous nephropathy [182]a n d
IgA nephropathy [183] ,a n dm u s c l ei nd e r m a t o m y o s i t i s
[184]. Autoreactive B cells have been identiﬁed within
these ectopic lymphoid follicles by their ability to bind
biotinylated self-antigens: thyroid antigens in the thyroid
gland in Hashimoto’s thyroiditis and Graves’ disease [156]
and Ro and La nuclear antigens in the salivary glands in
Sj¨ o g r e n ’ ss y n d r o m e[ 157].
Inmyastheniagravis,whereweaknessisusuallymediated
by antibodies to the acetylcholine receptor, there is minimal
lymphocytic inﬁltration at the neuromuscular junction, but
the thymus resembles an autoimmune target organ because
it contains ectopic B-cell follicles with germinal centres [185,
186] lying adjacent to thymic myoid cells expressing the
acetylcholine receptor [187]. In SLE, which is characterized
by the production of non-organ-speciﬁc autoantibodies,
follicularhyperplasiaoccursinthelymphnodes[188].These
lymph node hyperplastic germinal centres may represent
sites of clonal expansion of autoreactive B cells reactive to
ubiquitous self-antigens, such as those present in the nuclei
of all cells.
Here it is proposed that ectopic lymphoid follicles are
major sites of EBV persistence in chronic autoimmune
diseases, as has been shown in Sj¨ ogren’s syndrome [138],
inﬂammatory bowel disease [140], MS [141], and myasthe-
nia gravis [142].
4.ProposedScenariofortheDevelopment
of Chronic Autoimmune Diseases
The genetic background of autoimmunity is clearly complex
and involves epistatic interactions between genes [189]a n d
epigenetic modiﬁcation of gene expression [190]. Genetic
factors contributing to the development of chronic autoim-
mune diseases can be divided into those that confer a gen-
eral predisposition to autoimmunity and those that confer
susceptibility to speciﬁc autoimmune diseases. A general
predisposition to autoimmunity is manifested by the inc-
reased occurrence of various autoimmune diseases in indi-
viduals with a given autoimmune disease and in their blood
relatives [191–195]. Indeed there is evidence that this gen-
eral predisposition to autoimmunity is inherited as a Men-
delian dominant trait [191]. Here it is proposed that genet-
ically determined CD8+ T-cell deﬁciency, with consequent
impairment of CD8+ T-cell control of EBV-infected B cells,
is the mechanism underlying this general predisposition
to autoimmunity (Figures 3 and 4). For genes conferring
susceptibility to speciﬁc autoimmune diseases, the most
widely characterized are speciﬁc alleles of HLA class II and
less frequently HLA class I genes [196]. The mechanism
underlying this is unclear but the most likely explanation
is that the HLA molecules encoded by the speciﬁc alleles
determine which self-antigens (and therefore which organs)
are recognized by T cells that have been activated by
crossreacting foreign antigens or modiﬁed self antigens. The
following scenario describes how a genetic deﬁciency of
CD8+ T cells might lead to the development of chronic
autoimmune diseases after infection with EBV. This is
based on the EBV-infected autoreactive B cell hypothesis of
autoimmunity, which proposes that, in genetically suscep-
tible individuals, EBV-infected autoreactive B cells seed the
target organ where they produce pathogenic autoantibodies
and provide costimulatory survival signals to autoreactive
T cells [5]. It is important to clarify here that what is
proposed is that EBV is essential (through infection of
autoreactive B cells), but not necessarily the only environ-
mental agent required for the development of autoimmune
diseases. For example, gluten exposure is a prerequisite
for coeliac disease. Particular infectious agents other than
EBV might also be needed to activate autoreactive T
cells through molecular mimicry in particular autoimmune
diseases.
A genetic deﬁciency of CD8+ T cells would exert its
eﬀect from the time of primary EBV infection in the tonsil
by prolonging the survival and proliferation of infected B
lymphoblasts and germinal centre B cells and the survival
of plasma cells replicating the virus. This would increase the
probability of clonal expansion of EBV-infected autoreactive
B cells. It is proposed that EBV-infected autoreactive B cells
lodgeandpersistintheorgancontainingtheselfantigenthey
recognize. Depending on the disease-speciﬁc HLA class II
or class I alleles carried by a particular person, exposure to
foreign agents (including EBV itself) leads to the activation
of T cells which cross-react with self antigens and traﬃc
into the organ containing these self antigens where they are
reactivated by EBV-infected B cells presenting self antigens
(Figures 1 and 4). These EBV-infected B cells produce
pathogenic autoantibodies and also provide costimulatory
survival signals to the autoreactive T cells, thereby inhibiting
the activation-induced T-cell apoptosis which normally
occurs when autoreactive T cells enter the target organ [168,
169]. The autoreactive T cells orchestrate an immune attack
on the target organ through the recruitment of macrophages
and additional B cells. Self antigens released by this attack
lead to spreading of autoreactivity to other autoantigens
in the target organ. Repeated T-cell attacks on the target
organ supported by local EBV-infected B cells lead to the
development, within the target organ, of ectopic B-cell
follicles with germinal centres generating more autoreactive
B cells. The autoimmune process itself could foster the
survival and proliferation of EBV-infected autoreactive B
cells in the target organ by releasing self antigens and
giving CD4+ T-cell-help, which would complement the BCR
and CD40 receptor signalling already provided by EBV-
e n c o d e dL M P 2 Aa n dL M P 1 ,r e s p e c t i v e l y[ 197]. This could
lead to a vicious circle wherein EBV-infected autoreactive B
cells promote autoimmunity, which in turn promotes EBV
infection in the target organ. With prolonged high EBV load,
T-cell exhaustion would supervene, further compromising
the CD8+ T-cell control of EBV and further increasing the
EBV load. Deprivation of sunlight and vitamin D would also
aggravate the CD8+ T-cell deﬁciency and impaired control
of EBV (Figure 3).8 Autoimmune Diseases
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Lingual tonsil
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Pharyngeal tonsil
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Crohn’s disease
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Figure 4: Proposed sequence of events leading to the development of chronic autoimmune diseases. In individuals with a genetic deﬁciency
ofCD8+Tcells(carriedby“Autoimmunegenes”)andwithHLAclassIIgenespredisposingtoidiopathicdilatedcardiomyopathy(HLA-DR4
[206]), primary biliary cirrhosis (HLA-DR8 [207]), and Crohn’s disease (HLA-DR7 [208]), primary EBV infection, particularly if delayed
(Late), leads to the infection of autoreactive B cells, which accumulate in the target organ where they reactivate autoreactive T cells that
orchestrate an autoimmune attack on the organ. For simplicity these depictions focus on the role of CD8+ T-cell deﬁciency, EBV infection
and selected HLA alleles and do not include interactions with other genetic and environmental factors that may also contribute to the
pathogenesis of autoimmune diseases.
5.Testing the Hypothesis
5.1. Is EBV Infection Necessary for the Development of Chronic
Autoimmune Diseases? If EBV infection is necessary for the
development of chronic autoimmune disease it should be
possible to prevent and successfully treat these diseases by
controlling EBV infection [198].
5.1.1. Prevention. Vaccination of healthy EBV-seronegative
young adults with recombinant gp350 is eﬀective in prevent-
ing thedevelopment ofinfectious mononucleosis inducedby
EBV infection, although it does not prevent asymptomatic
EBV infection [199]. The vaccinated subjects showed sero-
conversion to anti-gp350 antibodies which persisted >18
months and were probably responsible for the protectiveAutoimmune Diseases 9
eﬀect because anti-gp350 antibody neutralizes EBV infec-
tivity [200]. Vaccination with gp350 might decrease the
incidence of chronic autoimmune diseases by reducing the
numberofBcellsinfectedbyEBV,andtherebydecreasingthe
probability of infected autoreactive B cells, during primary
infection.
5.1.2. Treatment. There are potentially 3 ways to treat chron-
ic autoimmune diseases by controlling EBV infection: (1)
B-cell depletion with monoclonal antibodies; (2) boosting
immunity to EBV; (3) antiviral drugs. B-cell depletion with
rituximab eliminates not only EBV-infected B cells but
also uninfected B cells, which normally confer protective
immunity against infectious agents. Improvement of an
autoimmune disease with rituximab therapy would be con-
sistentwithanessentialroleofEBVinthedevelopmentofthe
disease but would not constitute proof because the beneﬁcial
eﬀect could be mediated by the elimination of autoreactive B
cells not infected with EBV. More convincing evidence for an
essential role of EBV would be eradication of autoimmune
diseases by boosting immunity to EBV or by treatment
with antiviral drugs. Humoral immunity to EBV could be
boosted by vaccination with gp350 or administration of
humanized or human monoclonal antibody against gp350.
CD8+ T-cell immunity could be boosted by the intravenous
infusion of autologous EBV-speciﬁc cytotoxic CD8+ T cells
after expansion in vitro [201] or by the administration of
agents such as interleukin-7, which expands the population
of functional virus-speciﬁc CD8+ T cells in chronic viral
infection [202]. With regard to antiviral drugs, treatment
with aciclovir and related drugs, which inhibit herpesvirus
DNA polymerase, is likely to have only a limited beneﬁcial
eﬀect in chronic autoimmune diseases because these drugs
act on EBV only when it is using its own DNA polymerase
to replicate its DNA. This will apply only to lytically infected
cells but not to latently infected ones, which replicate EBV
DNA through the use of EBV nuclear antigen 1 (EBNA1) to
engage host cell DNA polymerase. One strategy to overcome
this would be ﬁrst to administer rituximab to eliminate as
many EBV-infected B cells as possible and to follow this with
long-term antiviral drug therapy. An alternative approach is
to target LMP1 [203], LMP2A, or EBNA1 [204] to inhibit
EBV in latently infected cells. It has also been suggested that
retroviral integrase inhibitors might be eﬀective against EBV
in autoimmune diseases [205]. If EBV infection of B cells in
the target organ underpins the development of autoimmune
diseases, eﬀective antiviral drugs have the potential to be
curative.
5.2.AreEBV-InfectedBCellsintheTargetOrganAutoreactive?
Whether EBV-infected B cells in the target organ are autore-
active could be addressed by determining whether they bind
biotinylated self antigens in the same way that intrathyroidal
germinal centre B cells speciﬁcally bind thyroid antigens in
autoimmune thyroid disease [156].
5.3. Does CD8+ T-Cell Deﬁciency Underlie the Development
of Chronic Autoimmune Diseases following EBV Infection?
Whether CD8+ T cell deﬁciency underlies the development
of chronic autoimmune diseases following EBV infection
could be addressed by the following experiments: (1)
prospective studies to determine whether CD8+ T cell deﬁ-
ciency precedes the development of autoimmune diseases;
(2) determining whether genetic variants associated with a
decreased number of CD8+ T cells, such as the A allele of
rs2524054 in HLA-B [63], predispose to chronic autoim-
mune diseases; (3) examining whether autoimmune diseases
can be successfully treated by the intravenous infusion
of autologous EBV-speciﬁc cytotoxic CD8+ T cells after
expansion in vitro or by the administration of interleukin-
7 to boost CD8+ T-cell immunity.
5.4. Does Vitamin D Deﬁciency Contribute to the Develop-
ment of Autoimmune Diseases by Depleting CD8+ T Cells?
Whether vitamin D deﬁciency contributes to the develop-
ment of autoimmune diseases by depleting CD8+ T cells
couldbetestedbydeterminingwhethertreatmentofvitamin
D deﬁciency in patients by dietary supplementation or
exposure to sunlight increases the CD8+ T cell response
to EBV, decreases the EBV load and produces clinical
improvement.
6. Conclusions
CD8+ T-cell deﬁciency is a general feature of chronic au-
toimmune diseases and also occurs in healthy blood rel-
atives of patients with these diseases. It is proposed that
this deﬁciency is genetically determined and underlies the
development of chronic autoimmune diseases by impairing
CD8+ T-cell control of EBV infection, with the result that
E B V - i n f e c t e da u t o r e a c t i v eBc e l l sa c c u m u l a t ei nt h et a r g e t
organ where they produce pathogenic autoantibodies and
provide costimulatory survival signals to autoreactive T cells.
Autoimmunity is postulated to evolve in a series of steps
culminatinginthedevelopmentofectopiclymphoidfollicles
containing EBV-infected autoreactive B cells in the target
organ. It is also proposed that deprivation of sunlight and
vitamin D facilitates the development of autoimmune dis-
eases by aggravating the CD8+ T cell deﬁciency and thereby
further impairing control of EBV. The hypothesis makes
predictions which can be tested, including the prevention
and successful treatment of chronic autoimmune diseases by
controlling EBV infection.
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